Ionis Pharmaceuticals (IONS) said late Thursday the US Food and Drug Administration has approved Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.
The syndrome is genetic form of severe hypertriglyceridemia that can result in potentially life-threatening conditions, the company said.
The drug, also called olezarsen, was approved based on data from a phase 3 clinical trial in which it reduced triglyceride levels 42.5% from baseline to six months, the company said.
Shares of the company were up 7.5% in Friday's premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。